

## Transparency notification received from The Capital Group

**Mechelen, Belgium; 3 March 2021; 22.15 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.**

Pursuant to Belgian transparency legislation<sup>1</sup>, Galapagos received a transparency notification on 26 February 2021 from The Capital Group Companies, Inc., who notified that it holds 9.91% of the current 65,411,767 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed below the 10% threshold of Galapagos' voting rights by disposing of voting securities on 22 February 2021. The full transparency notice is available on the Galapagos website.

### About Capital Group

Capital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. ("CGII"), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International Sàrl; and Capital International K.K.), which all together hold 6,483,973 of Galapagos' voting rights, consisting of ordinary shares, which represents 9.91%.

### About Galapagos

Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at [www.glpq.com](http://www.glpq.com).

### Contacts

#### Investors:

Elizabeth Goodwin  
VP Investor Relations  
+1 781 460 1784

Sofie Van Gijssels  
Senior Director Investor Relations  
+32 485 19 14 15  
[ir@glpg.com](mailto:ir@glpg.com)

#### Media:

Carmen Vroonen  
Global Head Communications & Public Affairs  
+32 473 824 874

Anna Gibbins  
Senior Director Therapeutic Areas Communications  
+44 7717 801900  
[communications@glpg.com](mailto:communications@glpg.com)

---

<sup>1</sup> Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market